Daiichi-Sankyo Co. Ltd.

Leading Practices

No leading practice identified for this company. 

Changes Compared to Index 2008

• Daiichi Sankyo was not evaluated in Access to Medicine Index 2008.
• Daiichi Sankyo was actively involved in Ranbaxy’s production quality improvement initiatives during the period of analysis.
• A range of philanthropic activities were introduced in Tanzania and other African countries during the period of analysis.

Suggested Areas for Improvement

• Daiichi Sankyo has no formal representation of ATM strategies at senior management level or annual reporting of policies, objectives and performance in this area.
• The company’s R&D focus on Index Disease products, especially for NTDs, is lower than some other Japanese companies.
• Daiichi Sankyo has no intra-country tiered-pricing models in China, India and Thailand where its products are sold.
• The company’s current disclosure on public policy positions in the Index Countries where it operates is low.
• Daiichi Sankyo‘s  Index Country outreach for its  existing two products relevant to the Index Diseases (an ischemic heart disease product and broad spectrum antibiotics) is lower than optimal, especially given Ranbaxy*’s manufacturing and distribution capacity.

* Ranbaxy’s initiatives in this area are covered separately under the generics companies section of this report. Daiichi Sankyo holds 63% of Ranbaxy’s shares.